This study assessed whether relatives with low bone mineral density (BMD) could be identified in five large families using historical, biochemical, and genetic markers for osteoporosis. Fifty of 65 relatives had their bone density and bone turnover markers measured, together with an assessment of their risk factors for osteoporosis. Only 33% (5115) of siblings, 50% (6/12) of children and 43% (10I23) of nephews and nieces had entirely normal BMD. There was no difference in life-style risk factors for osteoporosis, history of previous fractures or body mass index between normal subjects and those with osteopenia or osteoporosis. Osteopenic individuals had a significantly higher than normal osteocalcin value. Within families, there was no clear association between BMD and any of the genetic markers (vitamin D receptor gene polymorphisms, COL lAl and COL 1A2 polymorphisms of the collagen gene), either alone or in combination. The addition of genetic markers to the other risk factors for low BMD did not improve the prediction of BMD. In conclusion, we suggest that the presence of osteoporosis in a first degree relative should be one of the clinical indications for bone density measurement as the individuals at risk would not be picked up by other methods.
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Keywords: genetics; osteoporosis; bone mineral density; risk factors Osteoporosis is characterised by a decrease in bone mineral density (BMD) and microarchitectural deterioration of the bone structure leading to a higher susceptibility to fractures.' The burden of fractures is substantial, both from a personal and public healthcare point of view. For the clinically important hip fracture, there is a 1-year mortality following fracture of 5-20% and more than 50% of survivors will be incapacitated.' The annual economic burden to the health services has been estimated at £742 million.2 Fracture risk is determined by BMD and numerous studies have shown that this increases progressively as BMD declines. 36 Despite advances in therapy, reversal of bone loss in established osteoporosis remains difficult, and a better strategy would be to prevent bone loss before it occurs which would require identification of individuals at risk. One approach would be to identify genetic markers for osteoporosis which could form the basis of a primary prevention programme. Evidence for a genetic influence on bone density comes from two types of clinical studies based on twins and small families. Studies in twins have shown that BMD is more significantly correlated in monozygotic than dizygotic twins at the spine and proximal femur.7 8 These studies have calculated an estimate of heritability of bone mass (the proportion of the variation in bone mass that can be explained by genetic factors after adjustment for age and years since menopause) of approximately 90% in the lumbar spine and 70% in the femoral neck. In family studies, 45-60% of the variance of bone density within a family was attributable to heredity. 9 10 Given the substantial genetic contribution to the determination of an individual's BMD, it would not be surprising if low bone mass were also more prevalent among close relatives of patients with osteoporosis. Several studies have shown that healthy offspring of osteoporotic mothers have a lower BMD than would be expected compared to healthy offspring of normal mothers." 12 Jouanny and colleagues'3 quantified the relative risks of children having a low BMD if their parent(s) had low BMD, after adjusting for environmental factors. A low BMD in a mother increased the relative risk of low BMD in her daughter to 5.15 and for a father-son pair, the relative risk was 3.79. If both parents were low, the relative risks of low BMD increased even further to 7.54 for a son and 34.4 for a daughter.
In addition to these clinical studies, the vitamin D receptor gene has recently been suggested as a marker for osteoporosis, with the BB genotype (absence of the restriction site on both alleles) having a lower BMD,4'l6 although this has not been a universal observation.'7"-These studies have involved twins14 15 17 and unrelated individuals with severe osteoporosis'8 20 but not large family groups. The vitamin D receptor gene may also influence peak bone mass in women22 23 and this could be a useful marker in familial osteoporosis where the problem may be one of low peak bone mass rather than accelerated age-/menopause-related bone loss.
Abnormalities in the collagen gene may also lead to osteoporosis because of the intimate relationship between collagen and bone. Osteoporosis might be regarded as the less severe end of the spectrum of osteogenesis imperfecta24 25 which is almost always due to mutations in type I collagen.26
In the present study of Of the three relatives with a low-trauma wrist populations." In our study, the osteopenic individuals had a higher osteocalcin than the normal individuals suggesting an increased bone turnover but the range of values was wide and would not be helpful as a diagnostic test. Biochemical markers have also been used as a predictor of future bone loss'4 and the subjects in this study are currently being followed to determine whether they continue to lose bone or whether their problem was one of low peak bone mass. This would allow an assessment of whether their baseline bone markers were helpful in determining future bone loss. We recognise that there are several problems with this study. Firstly, not all of the available family members were studied but the proportion with a low BMD is high and the measured prevalence may be a slight overestimate. The second problem concerns the identification of the proband. We could have initially seen one of the siblings with a normal BMD (instead of our proband) and would have been falsely re-assured. It follows that an area for further research is to determine the incidence of low BMD in the community, especially in men, to see if this prevalence of suboptimal bone mass in these relatives is truly a reflection of the genetic factors predisposing to osteoporosis or whether environmental factors are equally important.
In conclusion, we would suggest that the presence of osteoporosis in a first degree relative should be one of the clinical indications for bone density measurement although this is not current policy.37 This would allow appropriate advice about hormone replacement therapy and life-style in an attempt to reduce perimenopausal bone loss and to maximise peak bone mass. This would inevitably lead to an increase in health service workload and have substantial cost implications.
